Member Info for one4one

Your warped ! procedures are procedures & the capillary of the FDA "Estonia" will implement them, the critical control point being patient Safety🐭

Estonia is out of the equation until the Fda gives the green light & then Estonia will have access to hemogenyx blue print,

the partnership with Celin will/should be granted by Estonia FDA clinical trial procedures and may be granted fast track designation as hemogenyx has done the R&D🐭

Https://www.proactiveinvestors.co.uk/companies/news/1065642/helix-exploration-is-advancing-big-impact-helium-exploration-in-the-united-states-1065642.html

Https://www.lse.co.uk/rns/HEX/helix-expands-rudyard-leasehold-cf10felo9xgff0f.html

the rns says it all,

Pre registrar.....i got timed out i think the pc has got dementia

Ok the discounted + warrants are to attract institutional investors, the valuation is a negotiated deal the placing price is the floor but not the ceiling the sp may drift t/wards the placing price if the i/investor forward sells into the market/further dilution /cash burn of which the E o y results will reveal/ Hold on to your Hats gentlemen and take a seat at the table as the game is about to begin ...."faites vos jeux.....jhfh is a sloth being mugged by a snail lol🐭

Nps4 is getting twitchy lol......the market has valued the sp @ £7.50/placings !

Pending your volume of holdings will haemorrhage your wallet, school of thought the placings @ £7.50 so why can you not buy @ that price ?

Missed the RNS no 3 then poetic:-0

Been here since David frazer pumped the tremendous copper project then bh took the reigns and aligned with the gold/the cogs of the mill are still not turning & now the move to tungsten "yawn and still this sloppy outfit is a explorer

More like placing/a rehearsal of another consolidation/no in coming revenue/remains a exploration company

Lets breakdown the speculating HG-CT-I is a clinical term adopted by Hemogenyx HG-CT-1 is the same therapy as CD19FLT33.

Has the Patients been infused with a full dose or a half dose/Half Dose would be a strong case for survival from the CRS toxins

car-t wanes after a definitive time, so a second dose will be vital to prevent relapse. "Time = $ pharma industry will be monitoring

as further adults are enrolled pending metabolism a uprated dose/paediatric has a stronger immune defence Mechanism/survival rate

in a nutshell blood cancer car-t therapy attacks the cell molecules thou it does not penetrate tumours, car-t is still in the infancy stage

as the science evolves it will eradicate & Tweet the therapy 🐭

Https://www.cruxinvestor.com/posts/helix-exploration-lsehex-self-funding-model-for-helium-exploration-7306

Https://www.msn.com/en-gb/money/other/has-the-market-misjudged-relx/ar-AA1XdvKr?ocid=msedgdhp&pc=HCTS&cvid=69a2101cdf76403ab6b94056166e90ab&ei=40

Follow the Law of Gravity🐭

The Company will seek to implement the clinical trials for pediatric AML at the newly established clinical site. This area is of particular concern,🐭

Expansion into Pediatric Indications:

Pediatric AML and ALL: The Company is seeking to expand the HEMO-CAR-T indication to include pediatric acute myeloid leukemia (“AML”) and a subset of pediatric acute lymphoblastic leukemia (“ALL”) patients. An amendment to the clinical protocol to include pediatric AML is currently under review by third party experts. If approved, the Company will seek to implement the clinical trials for pediatric AML at the newly established clinical site. This area is of particular concern, and there is an urgent need for effective treatments for these conditions, which the Company believes HEMO-CAR-T will be able to provide.🐭

Snippet from operations update Clinical Trials Progress:Clinical Trials Progress:🐭

Additional Clinical Trial Site: The Company has added an additional prestigious US medical center to its list of clinical trial sites. This will enhance the scope and expedite the timeline for the implementation of clinical trials.

Clinical Site Setup: The setup of clinical sites at the University of Pennsylvania (“PENN”) and the new medical centre is underway. This multi-step process involves thorough internal reviews by the science review committee and the internal review board of both clinical sites, as well as budget negotiations and logistics planning. The Company continues to work with Prevail Infoworks, a contract research organization (“CRO”), to manage and oversee the planning for the clinical trials.

Additional Clinical Trial Site: The Company has added an additional prestigious US medical center to its list of clinical trial sites. This will enhance the scope and expedite the timeline for the implementation of clinical trials.

Clinical Site Setup: The setup of clinical sites at the University of Pennsylvania (“PENN”) and the new medical centre is underway. This multi-step process involves thorough internal reviews by the science review committee and the internal review board of both clinical sites, as well as budget negotiations and logistics planning. The Company continues to work with Prevail Infoworks, a contract research organization (“CRO”), to manage and oversee the planning for the clinical trials.

Bullocks the problem is with the secondary c/site🐭

Stay calm losta inhale the positive/exhale the negative, the critical control point is the patients Safety ! yes Mda will start a fresh...app for funding/IRB/DSMN approval and the colossal paper work chain it is not of case of rolling up your sleeves and having a infusion🐭